Pertussis Vaccine Market Report
First published: 10 October 2024 | Last updated: 25 May 2026 | Report Code: pertussis-vaccine
Pertussis Vaccine Market — USD 2.5 billion in 2023, Growing to USD 4.41B by 2033 at 5.7% CAGR
This market report provides an in-depth analysis of the Pertussis Vaccine market from 2023 to 2033, highlighting market size, growth trends, industry dynamics, and regional insights.
Key Takeaways
- Global market value rises from $2.50 Billion in 2023 to $4.41 Billion in 2033 at a 5.7% CAGR.
- North America is largest regional market, while no single fastest-growing region is stated because regional CAGR differences remain within 0.15 percentage points.
- Europe expands from $0.69 Billion to $1.21 Billion between 2023 and 2033, reflecting sustained demand.
- Acellular and combination vaccines, plus public immunization programs, are central to market momentum.
- Major manufacturers include Sanofi Pasteur, GlaxoSmithKline, Merck & Co., and Pfizer.
Pertussis Vaccine Market Report — Executive Summary
North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. The Pertussis Vaccine market is driven by persistent public health programs, advances in vaccine formulations, and expanding immunization coverage across age groups. Market value stands at $2.50 Billion in 2023 and is forecast to reach $4.41 Billion by 2033 at a 5.7% CAGR. Demand is supported by preference shifts toward acellular vaccines and concerted vaccination campaigns involving government and non-profit organizations. Distribution channels such as hospitals, retail pharmacies, and e-commerce influence accessibility, while regulatory requirements guide product development and safety profiles. Leading firms—Sanofi Pasteur, GlaxoSmithKline, Merck & Co., and Pfizer—play prominent roles through product portfolios and partnerships. Key challenges include addressing vaccine hesitancy and navigating complex approval pathways. The report segments the market by vaccine type, age group, administration route, distribution channel, and end user, providing stakeholders with actionable insights for product positioning and investment planning.
Key Growth Drivers
- Public immunization initiatives and government vaccination programs expanding coverage and procurement.
- Shift toward acellular vaccine formulations driven by safety and tolerability considerations.
- Increased distribution through hospitals, retail pharmacies, and e-commerce enhancing access.
- Ongoing product innovation and partnerships among leading manufacturers supporting pipeline and supply stability.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $2.50 Billion |
| CAGR (2023-2033) | 5.7% |
| 2033 Market Size | $4.41 Billion |
| Top Companies | Sanofi Pasteur, GlaxoSmithKline, Merck & Co., Pfizer |
| Published Date | 10 October 2024 |
| Last Modified Date | 25 May 2026 |
Pertussis Vaccine Market Overview
Customize Pertussis Vaccine Market Report market research report
- ✔ Get in-depth analysis of Pertussis Vaccine market size, growth, and forecasts.
- ✔ Understand Pertussis Vaccine's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Pertussis Vaccine
What is the Market Size & CAGR of Pertussis Vaccine Market Report market in 2023?
Pertussis Vaccine Industry Analysis
Pertussis Vaccine Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Pertussis Vaccine Market Report Market Analysis Report by Region
Europe Pertussis Vaccine Market Report:
Europe grows from $0.69 Billion in 2023 to $1.21 Billion in 2033. Regional growth is driven by organized vaccination programs, emphasis on acellular formulations, and regulatory frameworks that influence uptake and product approvals.Asia Pacific Pertussis Vaccine Market Report:
Asia Pacific grows from $0.52 Billion in 2023 to $0.91 Billion in 2033. Market momentum is underpinned by expanding public health campaigns, rising awareness of pertussis vaccination across age groups, and improving distribution networks.North America Pertussis Vaccine Market Report:
North America is largest regional market, rising from $0.83 Billion in 2023 to $1.47 Billion in 2033. This expansion reflects mature immunization schedules, established procurement mechanisms, and strong clinical and distribution infrastructure supporting vaccine availability.South America Pertussis Vaccine Market Report:
Latin America grows from $0.23 Billion in 2023 to $0.41 Billion in 2033. Demand is shaped by government-led immunization efforts, partnerships with international organizations, and widening access through healthcare facilities and pharmacies.Middle East & Africa Pertussis Vaccine Market Report:
Middle East and Africa grows from $0.23 Billion in 2023 to $0.41 Billion in 2033. Growth reflects scaled public health initiatives, targeted vaccination drives, and efforts to broaden supply and delivery channels despite regional access challenges.Tell us your focus area and get a customized research report.
Research Methodology
Pertussis Vaccine Market Analysis By Type
The Pertussis Vaccine market is largely driven by acellular vaccines, which are expected to rise from $1.72 billion in 2023 to $3.04 billion in 2033. Whole-cell vaccines maintain a significant presence, growing from $0.63 billion to $1.11 billion over the same period. Combination vaccines remain niche but are projected to expand slightly due to combination immunization schedules.
Pertussis Vaccine Market Analysis By Age Group
The largest segment in the Pertussis Vaccine market is infants, with an expected market growth from $1.33 billion in 2023 to $2.35 billion in 2033. Children and adults represent smaller segments but will see increased focus on vaccination during routine healthcare visits due to rising awareness.
Pertussis Vaccine Market Analysis By Administration Route
Injection remains the predominant administration route for Pertussis Vaccines, growing from $2.14 billion in 2023 to $3.78 billion in 2033. Oral vaccines, while less common, are projected to see gradual adoption due to preference for non-invasive methods.
Pertussis Vaccine Market Analysis By Distribution Channel
Hospitals are the leading distribution channel for Pertussis Vaccines, valued at $1.72 billion in 2023, with expectations to expand to $3.04 billion by 2033. Retail pharmacies and e-commerce are gradually gaining traction as alternative channels, particularly in regions seeking improved accessibility.
Pertussis Vaccine Market Analysis By End User
Healthcare providers dominate the end-user segment, comprising a substantial share. Government organizations and non-profit organizations also significantly contribute to the distribution and administration of the vaccine, focusing mainly on public health initiatives and childhood vaccination drives.
Pertussis Vaccine Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Pertussis Vaccine Industry
Sanofi Pasteur:
A leading biotechnology firm known for developing Vaccines and biologics, significantly contributing to global immunization efforts, including the Pertussis Vaccine.GlaxoSmithKline:
A major player in the vaccine industry focused on innovative vaccine development, including combination vaccines that incorporate pertussis components.Merck & Co.:
This company plays a critical role in the global vaccine market, offering several vaccines and continuously investing in research and development of Pertussis Vaccines.Pfizer :
Pfizer contributes to the pertussis vaccine market significantly, particularly in developing new formulations for various age groups, enhancing public health outcomes.We're grateful to work with incredible clients.
FAQs
What is the current market size of the Pertussis Vaccine market?
The market size for the Pertussis Vaccine market was $2.50 Billion in 2023, as reported in the input data provided for this analysis.
How big will the Pertussis Vaccine market be in 2033?
The Pertussis Vaccine market is projected to reach $4.41 Billion by 2033 according to the provided forecast figures for the 2023 to 2033 period.
What is CAGR of the Pertussis Vaccine market?
The reported compound annual growth rate (CAGR) for the Pertussis Vaccine market over 2023 to 2033 is 5.7% as specified in the input dataset.
Is there a single fastest Growing region in the Pertussis Vaccine Market Report market?
No single fastest-growing region is stated for the Pertussis Vaccine Market Report market because the top regional implied CAGR values are within 0.15 percentage points of each other, making the ranking too close to call reliably.
Which companies lead the Pertussis Vaccine market?
Top companies cited for the Pertussis Vaccine market include Sanofi Pasteur, GlaxoSmithKline, Merck & Co., and Pfizer as listed in the source data.
What are common distribution channels for pertussis vaccines?
Distribution channels highlighted include hospitals, retail pharmacies, and e-commerce, each contributing to vaccine accessibility and supply chain reach in different settings.
How are vaccine formulations influencing the market?
A shift toward acellular vaccines is noted, with these formulations favored for safety profiles and influencing adoption patterns among infants, children, adults, and pregnant women.
Why is vaccine hesitancy relevant to market dynamics?
Vaccine hesitancy affects uptake rates and public program effectiveness, posing a demand-side challenge that can influence immunization coverage and market growth.